GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (LSE:HLN) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Haleon (LSE:HLN) Future 3-5Y EPS without NRI Growth Rate : 7.81 (As of Jul. 23, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Haleon Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Haleon's Future 3-5Y EPS without NRI Growth Rate is 7.81.

Competitive Comparison of Haleon's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haleon's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Haleon's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Haleon  (LSE:HLN) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Haleon Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Haleon's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (LSE:HLN) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
LSE:HIK LSE:HCM LSE:INDV LSE:AGY LSE:ANCR LSE:EAH LSE:STX LSE:PXS AQSE:ANA LSE:CEL ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA SHSE:688506
Traded in Other Exchanges
HLNCF:USA HLN:USA HLN1:Mexico HLNl:UK H6D0:Germany
Address
The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
Website
https://www.haleon.com
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.